Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) PT at $4.79

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received a consensus rating of “Hold” from the eleven analysts that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $4.79.

Separately, StockNews.com initiated coverage on Marinus Pharmaceuticals in a report on Wednesday, March 26th. They set a “sell” rating on the stock.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.55 on Monday. The company’s 50-day simple moving average is $0.55 and its two-hundred day simple moving average is $0.71. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $9.07. The company has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in shares of Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares during the last quarter. Franklin Resources Inc. raised its holdings in Marinus Pharmaceuticals by 34.9% in the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. Deltec Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at about $107,000. Jacobs Levy Equity Management Inc. grew its position in shares of Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares during the last quarter. Finally, Suvretta Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares during the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.